MomentumTradingHQ.com Featured Stock for the Week of 9/1/25 - 9/5/25: Nektar Therapeutics (NKTR) Day Trade Return of 7.9%

Nektar Therapeutics shares rose 18% in Thursday trading after late-stage trial results from Sanofi's (SNY) competing atopic dermatitis drug, amlitelimab, failed to meet investor expectations. Nektar is currently developing its own atopic dermatitis treatment and said in June that its phase-2b study of Rezpegaldesleukin met primary and key secondary endpoints.

Our proprietary real time alert services picked up NKTR's unusual stock and option volume Thursday morning. Depending on your favorite momentum indicator several opportunities presented themselves to get in to capture a portion of the daily return.

As shown in the chart below, a day trade entered at 11:30 am and closed at the end of the day would have gained 7.9%. The chart shows the indicators that were triggered as well as the time.

If you are interested in getting real time stock alerts sent to your email visit MomentumTradingHQ.com and subscribe to the indicator alert service that fits your trading style. There is currently a 7 day free trial.

If you are interested in receiving the Featured Stock blog visit MomentumTradingHQ.com and sign up for free.